机构：[1]Department of Oncology, Jilin Cancer Hospital, Changchun, China[2]Biotherapy Center, Sun Yat-sen University Cancer Center, Guangzhou, China[3]State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China[4]Department of Pancreatic Hepatobiliary Surgery, Fudan University Shanghai Cancer Center, Shanghai, China[5]Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China[6]Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China[7]Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China[8]First Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[9]Department of Gastroenterology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室消化内科河北医科大学第四医院[10]HUTCHMED Limited, Shanghai, China
第一作者机构：[1]Department of Oncology, Jilin Cancer Hospital, Changchun, China
推荐引用方式(GB/T 7714)：
Cheng Ying,Zhang Xing,Lu Ming,et al.Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(23_SUPPL):42-42.doi:10.1200/JCO.2024.42.23_suppl.42.
APA：
Cheng, Ying,Zhang, Xing,Lu, Ming,Shi, Si,Ye, Feng...&Su, Weiguo.(2024).Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study.JOURNAL OF CLINICAL ONCOLOGY,42,(23_SUPPL)
MLA：
Cheng, Ying,et al."Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study".JOURNAL OF CLINICAL ONCOLOGY 42..23_SUPPL(2024):42-42
医学